Oncotelic Therapeutics Inc (OTLC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OTLC SEC filings page.
This page shows Oncotelic Therapeutics Inc (OTLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The dominant mechanic is a balance-sheet transformation: reported earnings surged while operating cash flow remained negative and liquidity stayed extremely thin.
FY2025 net income reached$249.3M while operating income remained a loss of$3.2M , so the headline earnings were not generated by core operations. Operating cash flow was-$1.4M despite$111.6M of income tax expense, making earnings quality the central interpretive issue rather than profitability alone.
Total assets expanded from
Despite the larger equity base, short-term liquidity remains constrained: the current ratio was 0.1x and reported liquidity equaled 0.8 months of the latest annual operating outflow. The combination separates balance-sheet solvency from near-term financial flexibility.
Financial Health Signals
Oncotelic Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Oncotelic Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Oncotelic Therapeutics Inc used $0.01 of operating cash (-$1.4M OCF vs $249.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Oncotelic Therapeutics Inc generated $250K in revenue in Q2 2026.
Oncotelic Therapeutics Inc reported $388K in net income in Q2 2026. This represents an increase of 39.7% from the same quarter a year earlier. Against the prior quarter it is up 117.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Oncotelic Therapeutics Inc held $186K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Oncotelic Therapeutics Inc's ROE was 0.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Oncotelic Therapeutics Inc invested $345 in research and development in Q2 2026. This represents an increase of 16.2% from the same quarter a year earlier. Against the prior quarter it is down 56.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
OTLC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $250K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $345+16.2% | $795+167.7% | N/A | N/A | $297+17.9% | $297-38.1% | N/A | $480-97.7% |
| SG&A Expenses | $1.1M+1564.7% | $1.9M+1737.8% | N/A | $491K+511.1% | $66K-31.8% | $101K-39.5% | N/A | $80K+134.0% |
| Operating Income | -$844K-1178.7% | -$1.9M-1733.2% | N/A | -$491K+85.0% | -$66K+31.7% | -$101K+39.5% | N/A | -$3.3M-22760.3% |
| Interest Expense | $318K+53.2% | N/A | N/A | N/A | $208K+2373.6% | N/A | N/A | $8K-95.5% |
| Net Income | $388K+39.7% | -$2.2M-634.4% | N/A | -$1.0M+68.3% | $278K+232.4% | -$299K+26.9% | N/A | -$3.3M-2965.8% |
| EPS (Basic) | $0.00 | $0.00 | $0.59 | $0.00+100.0% | $0.00 | $0.00 | $0.00 | -$0.01 |
| EPS (Diluted) | $0.00 | $0.00 | N/A | N/A | $0.00 | $0.00 | N/A | -$0.01 |
| Diluted Shares (Avg) | 468M+3.3% | 444M+8.9% | N/A | N/A | 453M+12.8% | 407M+2.0% | N/A | 407M+2.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Income Tax.
OTLC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $394.8M+1379.5% | $394.0M+1377.2% | $393.1M+1373.5% | $28.2M+5.1% | $26.7M-10.9% | $26.7M-11.0% | $26.7M-11.1% | $26.8M-11.0% |
| Current Assets | $1.5M+961.6% | $2.1M+1552.1% | $1.2M+792.8% | $1.6M+574.8% | $138K-28.3% | $125K-45.9% | $134K-50.6% | $239K-34.6% |
| Cash & Equivalents | $186K+111.3% | $64K-19.7% | $89K+3.2% | $409K+174.5% | $88K+21.9% | $79K-58.1% | $86K-49.5% | $149K-44.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $2K-89.2% | $2K-89.2% | $51K+170.5% | $4K-79.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M-53.4% | $2.8M-53.4% | $2.8M-53.4% | $2.8M-53.4% |
| Total Liabilities | $131.3M+580.8% | $131.7M+576.1% | $131.4M+584.2% | $20.1M+7.7% | $19.3M+4.6% | $19.5M+4.1% | $19.2M+4.3% | $18.7M+6.3% |
| Current Liabilities | $17.9M-7.2% | $18.4M-5.5% | $18.1M-5.5% | $20.1M+22.8% | $19.3M+19.0% | $19.5M+18.0% | $19.2M+16.3% | $16.4M-4.4% |
| Non-Current Liabilities | $113.4M | $113.3M | $113.2M | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $2.3M+426.4% |
| Total Equity | $264.6M+3087.1% | $263.3M+3181.6% | $262.8M+3084.3% | $9.1M+2.2% | $8.3M-31.7% | $8.0M-32.2% | $8.3M-32.0% | $8.9M-29.5% |
| Retained Earnings | $209.4M+650.2% | $209.0M+645.2% | $211.2M+655.3% | -$39.1M-4.5% | -$38.1M-11.5% | -$38.3M-13.0% | -$38.0M-13.5% | -$37.4M-14.2% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
OTLC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$92K+26.9% | -$342K-105.0% | -$783K-653.7% | -$307K-114.4% | -$126K+51.8% | -$167K+27.9% | -$104K+72.1% | -$143K+42.5% |
| Stock-Based Compensation | N/A | $1.6M | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | $215K+59.0% | $317K+98.1% | $463K+1029.0% | $628K+185.5% | $135K-6.9% | $160K-36.0% | $41K-85.1% | $220K-34.3% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
OTLC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -337.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 155.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 0.1%-3.2pp | -0.8%+2.9pp | N/A | -11.6%+25.8pp | 3.4%+5.1pp | -3.7%-0.3pp | N/A | -37.3%-38.3pp |
| Return on Assets | 0.1%-0.9pp | -0.6%+0.6pp | N/A | -3.7%+8.6pp | 1.0%+1.7pp | -1.1%+0.2pp | N/A | -12.3%-12.7pp |
| Current Ratio | 0.08+0.1x | 0.11+0.1x | 0.07+0.1x | 0.08+0.1x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x |
| Debt-to-Equity | 0.50-1.8x | 0.50-1.9x | 0.50-1.8x | 2.22+0.1x | 2.32+0.8x | 2.43+0.8x | 2.33+0.8x | 2.11+0.7x |
| Asset Turnover | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Oncotelic Therapeutics Inc OTLC | FY2025 | N/A | $249.3M | N/A | $14.4M | — |
| Finch Therapeutics Group, Inc. FNCH | FY2023 | $107K | -$74.8M | N/A | $5.0M | — |
| ACCUSTEM SCIENCES INC ACUT | FY2025 | N/A | -$1.8M | N/A | $2.9M | — |
| Harvard Apparatus Regenerative Technology Inc. HRGN | FY2025 | $704K | -$6.9M | N/A | $34.5M | — |
Where Oncotelic Therapeutics Inc Ranks
Frequently Asked Questions
Is Oncotelic Therapeutics Inc profitable?
Yes, Oncotelic Therapeutics Inc (OTLC) reported a net income of $249.3M in fiscal year 2025.
What is Oncotelic Therapeutics Inc's return on equity (ROE)?
Oncotelic Therapeutics Inc (OTLC) has a return on equity of 94.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Oncotelic Therapeutics Inc's operating cash flow?
Oncotelic Therapeutics Inc (OTLC) recorded an outflow of $1.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oncotelic Therapeutics Inc's total assets?
Oncotelic Therapeutics Inc (OTLC) had $393.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Oncotelic Therapeutics Inc spend on research and development?
Oncotelic Therapeutics Inc (OTLC) invested $4K in research and development during fiscal year 2025.
What is Oncotelic Therapeutics Inc's current ratio?
Oncotelic Therapeutics Inc (OTLC) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Oncotelic Therapeutics Inc's debt-to-equity ratio?
Oncotelic Therapeutics Inc (OTLC) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oncotelic Therapeutics Inc's return on assets (ROA)?
Oncotelic Therapeutics Inc (OTLC) had a return on assets of 63.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oncotelic Therapeutics Inc's P/E ratio?
Oncotelic Therapeutics Inc (OTLC) trades at 0.1x earnings, its market capitalization divided by net income of $249.3M net income, FY2025. The market capitalization is $14.4M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Oncotelic Therapeutics Inc's price-to-sales ratio?
Oncotelic Therapeutics Inc (OTLC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $14.4M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Oncotelic Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Oncotelic Therapeutics Inc (OTLC) held $89K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.4M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Oncotelic Therapeutics Inc's Piotroski F-Score?
Oncotelic Therapeutics Inc (OTLC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oncotelic Therapeutics Inc's earnings high quality?
For every $1 of reported earnings, Oncotelic Therapeutics Inc (OTLC) used $0.01 of operating cash (-$1.4M OCF vs $249.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.